A randomized trial of trastuzumab deruxtecan and biology-driven selection of neoadjuvant treatment for HER2-positive breast cancer (ARIADNE).

Authors: Alexios Matikas, Bjorn Naume, Hans Wildiers, Maria Vittoria Dieci, Gabe S. Sonke, Andreas Karakatsanis, Aglaia Schiza, Kevin Punie, Christos Sotiriou, Matteo Lambertini, Claudio Vernieri, Guillermo Villacampa, Mats Hellström, Jonas C. S. Bergh, Johan Hartman, Theodoros Foukakis

Published: 2025-05-28

DOI: 10.1200/jco.2025.43.16_suppl.tps631

Source: Full article

---

Abstract

TPS631